In mice with DC-specific deletion of TGF-β receptor II, enhanced tumor protection, increased antigen presentation in tumor DC and improved IFN-γ production by tumor infiltrating CD8+ T cells were observed. This evidence concerns the gene CD8A and neoplasm.